Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin on Cardiac Function in T2D and Stage B Heart Failure
NCT03717194Phase 3Completed
- Start
- Jun 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ertugliflozin in type 2 diabetes mellitus (T2DM) and heart failure (HF) (2 arms). Primary endpoint: Left Ventricular Global Longitudinal Strain at 24 weeks. Started Jun 2019; status: completed.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on NCT03717194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03717194.